Liver Fibrosis Clinical Trial
Official title:
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year
by year, which has become an important public health problem in China. As NAFLD can progress
to Non-alcoholic steatohepatitis (NASH), cirrhosis and Hepatocarcinoma, the identification
and quantitative evaluation of liver steatosis and its dynamic changes are crucial. While
liver biopsy is still the gold standard in the diagnosis of NAFLD, its application is limited
because of the invasive procedure.The Transient Elastography(TE) combined with the Controlled
Attenuation Parameter(CAP) is a new non-invasive diagnostic method for fatty liver and liver
fibrosis.
In order to evaluate the diagnostic value of non-invasive assessment for the degree of liver
steatosis and staging liver fibrosis, this non-invasive method will be assessed by the golden
standard of liver biopsy among 400 NAFLD patients.The treatment protocols will be decided by
doctor and patient both (treatment protocols and medicine are not required). Blood routine,
blood biochemistry, abdominal ultrasound and Transient Elastography(TE) combined with the
Controlled Attenuation Parameter(CAP) are detected during the follow-up.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
| Recruiting |
NCT06051669 -
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
|
||
| Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
| Recruiting |
NCT06098417 -
Biomarkers in the Diagnosis and Prognosis of NAFLD
|
||
| Not yet recruiting |
NCT03623360 -
Functional MRI to Determine Severity of Cirrhosis
|
||
| Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
| Not yet recruiting |
NCT01133184 -
Improved Prevention of Perinatal Hepatitis B Transmission
|
Phase 4 | |
| Completed |
NCT00043303 -
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
|
Phase 2 | |
| Completed |
NCT03872024 -
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients
|
N/A | |
| Recruiting |
NCT05912179 -
Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
|
||
| Recruiting |
NCT04533828 -
68Ga-FAPI PET/CT in Liver Fibrosis Patients
|
Early Phase 1 | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Recruiting |
NCT03277651 -
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
|
N/A | |
| Completed |
NCT01707472 -
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
|
Phase 2 | |
| Not yet recruiting |
NCT05935488 -
Early Liver Disease Breath Detection
|
||
| Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
| Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
| Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
| Completed |
NCT01988753 -
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
|
||
| Completed |
NCT00049842 -
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
|
Phase 3 |